Regeneron Pharmaceuticals (STU:RGO) Common Stock: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
84 GF Score
Price €592.00
GF Value €785.48
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Common Stock?

Regeneron Pharmaceuticals STU:RGO -0.05% 84 Common Stock is €0 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 84/100 and a GF Value™ of €785.48 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's quarterly common stock stayed the same from Sep. 2025 (€0 Mil) to Dec. 2025 (€0 Mil) but then increased from Dec. 2025 (€0 Mil) to Mar. 2026 (€0 Mil).

Regeneron Pharmaceuticals's annual common stock increased from Dec. 2023 (€0 Mil) to Dec. 2024 (€0 Mil) but then declined from Dec. 2024 (€0 Mil) to Dec. 2025 (€0 Mil).

Regeneron Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Common Stock Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.09 0.09 0.10 0.09

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.09 0.09 0.09
STU:RGO
84GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Common Stock of €0 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Common Stock too high?
Regeneron Pharmaceuticals' current Common Stock is €0 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Common Stock compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Common Stock of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Common Stock is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €785.48, compared to a current price of €592.00 — trading 24.6% below its estimated fair value. The current Common Stock is €0 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Common Stock is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €592.00 is trading 24.6% below its estimated GF Value™ of €785.48. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:RGO:

  • Common Stock: €0 Mil
  • GF Value™: €785.48 vs. price of €592.00 (24.6% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
84GF Score

Get the complete analysis for STU:RGO

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€592.00
Price
€785.48
GF Value